Ranbaxy ties up with Schwarz for BPH drug

New Delhi, June 27: Ranbaxy Laboratories on Thursday announced it had tied up with Schwarz Pharma for development of a new drug for treatment of Benign Prostate Hyperplasia (BPH).

New Delhi, June 27: Ranbaxy Laboratories on Thursday announced it had tied up with Schwarz Pharma for development of a new drug for treatment of Benign Prostate Hyperplasia (BPH).
In a statment the company said the licencing deal for chemical entity RBx-2258 would allow Schwarz to obtain exclusive rights for marketing, development and distribution of the product in Europe, Japan and the United States while Ranbaxy would retain the rights for other markets.

"We welcome the new opportunity to develop a new compound to treat BPH and to collaborate with Ranbaxy which has an established reputation for its high standards of ethics and quality", Chief Executive Officer Schwarz Pharma AG Patrick Schwarz Schntte said.
Bureau Report

Zee News App: Read latest news of India and world, bollywood news, business updates, cricket scores, etc. Download the Zee news app now to keep up with daily breaking news and live news event coverage.
Tags: